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Background: Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing
evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin
cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential
contributor to small nerve fiber sensitization.
Methods: We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no
pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression
of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-
inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as
housekeeping gene. Additionally, we assessed DOR gene expression.
Results: All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and
healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and
lower leg within and between the groups and in FMS patient subgroups.
Conclusions: Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our
results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential
mechanism of small fiber pathology in FMS.
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Fibromyalgia syndrome (FMS) is a chronic pain condition
that is regularly associated with additional symptoms like
depressive mood, fatigue, and sleep disturbance [1]. The
pathophysiology of pain in FMS is incompletely under-
stood. In a recent study we showed that small nerve fiber
impairment is present in a subgroup of FMS patients [2];
these results were confirmed by others [3-6]. The reason
for small fiber pathology in FMS is unclear, and the ques-
tion is if local factors may contribute to nerve fiber dam-
age, fiber sensitization, and pain.
Cytokines are pleiotropic proteins that are key players
in pain induction and maintenance [7]. In the last years* Correspondence: ueceyler_n@ukw.de
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different neuropathic pain conditions. We found that in
affected skin samples of patients with length-dependent
idiopathic small fiber neuropathy the gene expression of
some pro-inflammatory cytokines is higher compared to
unaffected skin and that cytokine gene expression in the
distal skin of these patients is also higher compared to
healthy controls [8] while no such differences could be
found in patients with Fabry disease and associated small
fiber impairment [9]. Systemic cytokine expression has
extensively been investigated in patients with FMS, for
review see [10], however, so far no consistent pattern
has arisen. In skin of FMS patients, but not of healthy
controls, gene expression of the pro-inflammatory cyto-
kines tumor necrosis factor-alpha (TNF), interleukin (IL-)
1beta, and IL-6 was reported, using reverse transcriptionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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pression of skin opioid receptors in FMS patients com-
pared to controls [12].
Here we investigated cutaneous gene expression of
pro- and anti-inflammatory cytokines and of the delta
opioid receptor (DOR) in skin samples of patients with
FMS and compared our results with those of patients
with monopolar depression but without pain as disease
controls and with healthy controls. We hypothesized
that patients with FMS have a higher cutaneous gene ex-
pression of pro-inflammatory, algesic cytokines as the
basis of peripheral nerve fiber sensitization and that
DOR expression is reduced leading to an impaired effect
of endogenous opioids with increased pain.Methods
Patients and controls
Between 2007 and 2011 we prospectively recruited 25
patients with FMS (23 women, two men; median age:
59 years, range: 50–70). The diagnosis was made accord-
ing to the 1990 criteria of the American College of
Rheumatology (ACR) [13]. Patients were recruited from
all over Germany mainly by contacting self-help organi-
sations. After a telephone interview suitable patients
were invited to the Department of Neurology and were
examined neurologically and electrophysiologically to
check the in- and exclusion criteria as described earlier
[2]. Twenty-five patients could be included. Our inclu-
sion criteria were: male and female patients >18 years of
age; medically confirmed diagnosis of FMS according to
the 1990 ACR criteria; other possible differential diagno-
ses excluded (e.g. rheumatologic, orthopaedic). Exclusion
criteria were: other differential diagnoses explaining the
pain (e.g. rheumatologic, orthopaedic); other and add-
itional pain sources (e.g. pain due to arthritis); abnor-
malities in routine blood tests.
Depressive symptoms are frequently present in FMS
patients [1]. To control for possible confounding effects
of depression on study results, we additionally investi-
gated a group of ten patients (nine women, one men;
median age: 50 years, range 39–75) with monopolar
major depression without pain. These patients were en-
rolled between 2010 and 2011 at the Department of
Psychiatry at the University of Würzburg. An additional
group of 35 healthy controls was recruited. The group
consisted of 15 men and 20 women with a median age
of 51 years (20–84 years). Our study was approved by
the Würzburg Medical School Ethics Committee. Writ-
ten informed consent was obtained from all study partic-
ipants before enrolment. Data on clinical examination,
examination with electrophysiological measurements,
pain and depression questionnaires have been published
elsewhere [2].Skin punch biopsies
Five-mm diameter skin punch biopsies (Stiefel, Offenbach,
Germany) were obtained for histological analysis and for
quantitative real-time PCR (qRT-PCR) analysis as previ-
ously described [8]. Two biopsies were taken from each
participant (lateral proximal thigh and distal calf ). One pa-
tient with FMS refused a biopsy at the thigh and another
patient refused skin punch biopsy at all. Skin samples were
divided in two pieces. One was processed for immunohis-
tochemical analysis to determine intraepidermal nerve
fiber density. Methodology and results are presented else-
where [2]. The second half was flash-frozen in liquid ni-
trogen and stored at −80°C before further processing for
gene expression analyses.
RNA extraction from skin samples
RNA extraction followed a protocol described earlier [8].
After thawing skin samples were immersed in 1 ml TRI-
zol reagent (Invitrogen, Karlsruhe, Germany), and dis-
persed (Polytron 1600E, Luzern, Switzerland). Samples
were then incubated in 200 μl chloroform (25°C, 3 mi-
nutes) and were centrifuged (12.000 g, 15 minutes, 4°C).
Supernatants were mixed with 500 μl of isopropanol and
incubated again (25°C, 10 minutes). After another centri-
fugation step (12.000 g, 10 minutes, 4°C), the pellet
was washed with 75 % ethanol and spun again (7,500 g,
5 minutes, 4°C). The samples were air-dried and the
pellet was dissolved in diethylpyrocarbonate-treated water.
Afterwards, samples were incubated in a water bath (55°C,
10 minutes).
Reverse transcription PCR
All PCR reagents and cyclers were purchased from Ap-
plied Biosystems (Darmstadt, Germany). Extracted
mRNA (500 ng) was reverse transcribed using TaqMan
Reverse Transcription Reagents. Using 10 μl 10× PCR-
buffer, 6.25 μl Multiscribe reverse transcriptase, 2 μl
RNase inhibitor, 22 μl MgCl2, 20 μl dNTPs the reactions
were performed in the ABI PRISM 7700 Cycler at the
following conditions: 25°C, 10 min; 48°C, 60 min; 95°C,
5 min.
Gene expression analysis
TaqMan Universal Master Mix and 5 μl of cDNA were
used for qRT-PCR performed in the GeneAmp 7700 se-
quence detection system with the following gene specific
TaqMan Assays: TNF (ID: Hs00174128_m1), IL-6 (ID:
Hs00174131_m1), IL-8 (ID: Hs00174103_m1), and IL-10
(ID: Hs00174086_m1). Additionally, we assessed gene
expression of DOR (ID: Hs00538331_m1). 18sRNA (ID:
Hs99999901_s1) served as endogenous control. The
25 μl-reaction mix contained 12.5 μl TaqMan Master
Mix and 1.25 μl primer. The cycler conditions were:
50°C, 2 min; 95°C, 10 min; 45 cycles with 95°C, 15 sec;
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for blood measurements in addition a calibrator sample,
which was the blood sample of the control person whose
threshold cycles (Ct)-values were next to the calculated
mean of all control blood samples measured for each
primer. Samples were measured as triplicates, except for
18sRNA-values tested as duplicates. All plates were ana-
lyzed applying identical conditions. We used the com-
parative ΔCt-method (i.e. relating target gene expression
with individual 18sRNA expression) for individual as-
sessment. Lower ΔCT values (i.e. sample detection at
earlier PCR cycles) indicate higher gene expression. In
addition, we compared gene expression in the patient
and control groups using the ΔΔCt-method as previ-
ously described [14]. Here, the above mentioned ΔCt-
value is related to a calibrator sample which is the skin
sample from the healthy control group with a Ct-value
next to the group mean.
Statistical analysis
IBM PASW Statistics 21 software (IBM, Ehningen, Germany)
was used for statistical analysis. For data comparison
of non-normally distributed data the non-parametric
Mann–Whitney-U-test was applied. Data distribution
was tested with the Kolmogorov-Smirnov-test and by ob-
serving data histograms. Results of non-normally distrib-
uted data are given as median and range. P < 0.05 was
considered significant.
Results
Cytokine gene expression does not differ between FMS
patients and controls
Table 1 gives baseline data of the patient groups. The
investigated pro- and anti-inflammatory cytokines TNF,
IL-6, IL-8, and IL-10 as well as DOR were expressed in
skin from the upper and lower leg of patients with FMS,
depression, and healthy controls (Figure 1). No differ-
ence was found when comparing gene expression be-
tween groups (Figure 1) and of the upper and lower leg
(data not shown).
FMS subgroups do not differ with regard to skin cytokine
gene expression
As published earlier [2] the intraepidermal nerve fiber
density was reduced in a subgroup of the FMS patients.
When we divided the FMS group in patients withTable 1 Basic data of patient groups
FMS Depression Healthy controls
M, F 2, 23 1, 9 15, 20
Median age (range) [yrs] 59 (50–70) 50 (39–75) 51 (20–84)
Median disease duration
(range) [yrs]
21 (3–50) 23 (3–35) Not applicablenormal skin innervation and patients with abnormal dis-
tal or distal and proximal intraepidermal nerve fiber
density, we did not observe a difference in cytokine and
DOR gene expression between subgroups. Also, no cor-
relation was found between current pain intensity and
skin cytokine or DOR gene expression (data not shown).
Discussion
In this study we investigated the local gene expression of
selected pro- and anti-inflammatory cytokines and of
DOR in skin biopsies of patients with FMS, with mono-
polar depression, and of healthy controls. In contrast to
our hypotheses no increase in skin cytokine and no de-
crease in skin DOR gene expression was found in FMS
patients compared to patients with depression and to
healthy controls.
Systemic cytokine gene and protein expression has
been investigated extensively in FMS patients giving
contradictory results [10]. The hypothesis of the majority
of these studies is an increase in pro-inflammatory and
algesic cytokines in FMS patients as one contributor to
pain. The so far only study investigating skin cytokine
expression in FMS patients was published by Salemi
et al. [11]. The group used reverse transcription PCR
and reported the presence of the pro-inflammatory cyto-
kines IL-1beta, IL-6, and TNF in skin from the deltoid
region of FMS patients only while this was absent in
healthy controls [11]. This finding was interpreted in
terms of expression of algesic cytokines in skin of FMS
patients contributing to pain generation and mainten-
ance. In the current study we used qRT-PCR and show
that pro- and anti-inflammatory cytokines are not only
present in skin of patients with FMS but also in patients
with depression and healthy controls. The finding of
cytokine expression in healthy skin is in accordance with
previous reports [8,9]. One reason for the discrepancy in
results apart from the difference in biopsy sites com-
pared to the data of Salemi et al. may be that qRT-PCR
is the more sensitive method. In a study investigating
TNF immunoreactivity on formaline fixed skin biopsy
samples of patients with FMS and healthy controls also
no intergroup difference could be found [15].
In a second study Salemi et al. investigated DOR and
mu-opioid receptor gene expression in skin samples of
FMS patients compared to healthy controls. In this study
qRT-PCR was used [12]. Here, the authors reported an
almost 60fold higher gene expression in skin samples of
FMS patients compared to controls. Information on the
region of biopsy and the used primers were not provided
so that a direct comparison with our data obtained from
the upper and lower leg is not possible. Also, the
methods of data comparison between Ct values of FMS
patients and the control groups was different in both
studies, which may be the major reason for this
Figure 1 Boxplots show ΔCT values, i.e. relation of the CT value of the target normalized to the housekeeping gene 18sRNA, of tumor
necrosis factor-alpha (TNF, A), interleukin (IL)-6 (B), IL-8 (C), and IL-10 (D) and of the delta opioid receptor (DOR) (E) in skin samples of
the upper thigh (grey boxes) and the lower leg (white boxes) of patients with fibromyalgia syndrome (FMS), monopolar depression
without pain, and healthy controls. Lower ΔCt values indicate higher gene expression (i.e. earlier target copy detection). No intergroup
difference was found for any of the investigated targets.
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In our previous study we showed that small fiber im-
pairment is present in a subgroup of patients with FMS
[2]; our findings were confirmed by others [3-6]. The
open question is how reduced intraepidermal nerve fi-
bers may be linked with peripheral hyperalgesia and
pain. One possibility is that the remaining peripheral
nerve endings are sensitized by local influences such as
pro-inflammatory and algesic cytokines. However, we
did not find a positive support for this assumption inour study and suggest that other local factors like che-
mokines need to be investigated and also the ion chan-
nel repertoire of the remaining supposedly diseased
nerve fibers.
Our study has several limitations. The number of pa-
tients was small and with the relatively high variation of
the individual qRT-PCR values potential group differ-
ences may have been masked. The lack of difference in
gene expression patterns does not necessarily mean lack
of difference in the actually functional protein levels,
however, we were not able to conduct additional protein
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was also the reason for the selected panel of investigated
targets. Also, the assessment of whole skin samples in-
stead of separated skin cells may be another reason why
potentially present differences between groups may have
been missed.
Conclusion
We conclude that cytokine gene expression is not re-
stricted to FMS skin and that for the investigated cyto-
kines there is no intergroup difference that might have
been a plausible factor contributing to intraepidermal
nerve fiber sensitization. The possibility of a ganglionic
impact on fiber hyperexcitability and of other potential
mechanisms of peripheral nerve sensitization need to
be considered as well as other algesic mediators in
FMS skin.
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